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a b s t r a c t
Background: Recent evidence suggests that two doses of HPV vaccinesmay be as protective as three doses
in the short-term. We estimated the incremental cost-effectiveness of two- and three-dose schedules of
girls-only and girls & boys HPV vaccination programmes in Canada.
Methods: We used HPV-ADVISE, an individual-based transmission-dynamic model of multi-type HPV
infection anddiseases (anogenitalwarts, and cancers of the cervix, vulva, vagina, anus, penis andorophar-
ynx). We conducted the analysis from the health payer perspective, with a 70-year time horizon and 3%
discount rate, and performed extensive sensitivity analyses, including duration of vaccine protection and
vaccine cost.
Findings: Assuming 80% coverage and a vaccine cost per dose of $85, two-dose girls-only vaccination (vs.
no vaccination) produced cost/quality-adjusted life-year (QALY)-gained varying between $7900–24,300.
The incremental cost-effectiveness ratio of giving the third dose to girls (vs. two doses) was below
$40,000/QALY-gained when: (i) three doses provide longer protection than two doses and (ii) two-dose
protection was shorter than 30 years. Vaccinating boys (with two or three doses) was not cost-effective
(vs. girls-only vaccination) under most scenarios investigated.
Interpretation:Two-doseHPVvaccination is likely tobe cost-effective if its durationofprotection is at least
10 years. A third dose of HPV vaccine is unlikely to be cost-effective if two-dose duration of protection is
longer than 30 years. Finally, two-dose girls & boys HPV vaccination is unlikely to be cost-effective unless
the cost per dose for boys is substantially lower than the cost for girls.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND. IntroductionThe majority of high income countries have introduced
hree-dose routine human papillomavirus (HPV) vaccination
rogrammes [1]. Although most countries are vaccinating
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girls/women, only the US, Australia and one Canadian province
(Prince Edward Island) have included boys in their routine HPV
vaccination programmes. The most commonly used HPV vaccine
in high income countries (including Canada, the UK, the US and
Australia) is thequadrivalent [1],whichprotects againstHPV-16/18
(responsible for more than 70% of cervical cancers [2] and associ-
ated with other anogenital [3,4] and head and neck cancers [5])
and HPV-6/11 (associated with more than 85% of anogenital warts
[6]). Although vaccinating girls against HPV is expected to dramat-
ically reduce the burden of HPV-associated diseases [7,8] and to be
highly cost-effective [9–11], it nevertheless imposes an important
ﬁnancial strain on immunisation budgets. In Canada, HPV vaccine
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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epresents 40%of the total cost to fully immunise a girl from infancy
o adolescence (Dr. Bruno Turmel, Quebec Ministry of Health and
ocial Services, Personal communication) [12]. Decision-makers
ay thus be interested in the possibility of reducing doses of HPV
accine to invest the funds on improving coverage to underserved
opulations, male HPV vaccination or other immunisation pro-
rammes.
Recent evidence suggests that two doses of HPV vaccine may
e as protective as three doses in the short-term. A nested nonran-
omisedanalysiswithinaphase III randomisedclinical trial inCosta
ica suggested that two doses of HPV vaccine has similar high efﬁ-
acy against vaccine-type persistent infections as three doses, four
ears after vaccination [13]. More recently, a phase III randomised
rial examined the immunogenicity of two doses in girls 9–13 years
ompared to three doses in girls 9–13 years and three doses among
oung women 16–26 years. Results from the study showed that
ntibody responses for the vaccine-types among girls (9–13 years)
ho received two doses were noninferior to those among young
omen (16–26 years) who received three doses, over a period of
hree years after the last vaccine dose [14]. However, antibody
esponses to HPV-18 at two years and HPV-6 at three years were
igniﬁcantly lower for girls (9–13 years) who received two doses
s. girls (9–13 years) who received three doses. Because noninferi-
rity did not persist over time for all vaccine types when directly
omparing the two groups of girls aged 9–13 years, the authors of
he clinical trial, and those from the accompanying editorial [15],
oncluded that more data on duration of protection is required
efore reduced-dose schedules are recommended or implemented.
owever, such information will not be available for several years.
urthermore, data on duration of protection is not typically avail-
blewhennewvaccines are introduced (e.g., durationof three-dose
PV vaccine protection is still unknown).
Mathematical models are particularly well-suited and increas-
ngly used to provide timely evidence to inform immunisation
olicy-decisions when empirical data is scarce or incomplete
16], as they provide a formal framework to synthesise infor-
ation from various sources (e.g., clinical trials, epidemiological
tudies) to make predictions about the population-level effective-
ess and cost-effectiveness for different what-if scenarios (e.g.,
accinating girls-only or girls and boys, different durations of vac-
ine protection). To our knowledge, no model has examined the
ost-effectivenessof two-doseHPVvaccinationor theoptimal com-
ination of number of HPV vaccine doses and vaccination strategy
e.g., girls-only vs. girls and boys). The objectives of this study
ere to: (i) estimate the incremental cost-effectiveness of two-
nd three-dose schedules of girls-only and girls & boys HPV vac-
ination programmes, and (ii) identify the duration of two- and
hree-dose HPV vaccine protection necessary for a third dose to be
ost-effective.
. Methods
.1. Study design & economic analysis
HPV-ADVISE, an individual-based transmission-dynamicmodel
f multi-type HPV infection and disease, was used for model pre-
ictions [8,17,18]. Cost–utility analysis (cost/QALY-gained) was
hosen as the analytic technique and the analysis was performed
sing the healthcare payer perspective. Costs were inﬂated to
010 Canadian dollars using the Canadian Consumer Price Index
or Health. Costs and outcomes were discounted at 3%/year. A
0-year time-horizon was chosen for our reference-case (average
ife-expectancy of the ﬁrst cohort of vaccinated girls). Sensitiv-
ty analysis on the discount rate and time-horizon was conducted
s per good-modelling practice [19]. As suggested by WHO2 (2014) 5845–5853
guidelines [20,21], the Canadian per capita GDP was used as the
cost-effectiveness threshold. Hence, vaccination strategies below
$40,000/QALY-gained were considered cost-effective.
2.2. Strategies investigated
The incremental costs, beneﬁts, and cost-effectiveness ratios of
the following HPV vaccination strategies were examined:
(1) Two-dose girls-only vs. no vaccination
(2) Three-dose girls-only vs. two-dose girls-only vaccination
(3) Two-dose girls & boys vs. two-dose girls-only vaccination
(4) Three-dose girls & boys vs. three-dose girls-only or two-dose
girls & boys vaccination
In our base-case scenario, routine vaccination is given at 9 years
of age. Of note, all vaccination scenarios include a ﬁve-year three-
dose catch-up campaign for 14-year-old girls. Vaccination coverage
was 80%, similar to coverage in UK (79–91%) [22] and Australia
(64–80%) [23]. Vaccination coverage, ages at vaccination, vaccina-
tion schedules and the catch-up campaign are based on the current
girls-only HPV vaccination programme in Quebec, Canada [24].
However, vaccination coverage and the three-dose schedule were
varied in sensitivity analysis. HPV vaccination was introduced ﬁve
years ago in Canada (in 2008) and in many developed countries.
Hence, all changes in vaccination strategies are modelled to occur
during the 6th year of the programme. See Supplementary Fig. 1
for a detailed description of the vaccination strategies examined in
our base-case scenario.
2.3. Model structure
The model structure of HPV-ADVISE is described in great detail
elsewhere [8,17,18]. Brieﬂy, individuals in themodel are attributed
four different risk factors for HPV infection and/or disease: gen-
der, sexual orientation, sexual activity level and screening level.
Eighteen HPV-types are modelled individually (including HPV-
16/18/6/11/31/33/45/52/58). The diseasesmodelled are anogenital
warts and cancers of the cervix, vulva, vagina, anus, penis, and
oropharynx. Cytologywasused for cervical cancer screening,which
reﬂects current practice in Canada. Screening rates are a function
of a woman’s screening behaviour level, previous screening test
results, and age. Finally, direct medical costs and Quality-Adjusted
Life-Year (QALY) weights were attributed to outcomes (e.g., diag-
nosed lesions, cancer) over time.
2.4. Parameter values
Sexual behaviour, natural history and cervical screening
parameters were identiﬁed by ﬁtting the model to 782 sex-
ual behaviour, HPV epidemiology and screening data target
points, taken from the literature, population-based datasets,
and original studies [25–37] (see Van de Velde et al. [8]
and www.marc-brisson.net/HPVadviseCEA.pdf). Vaccine-type and
cross-protective efﬁcacy estimates were based on a recent meta-
analysis [38] (see Supplementary Table 1), and assumed to be
equal for two- and three-dose schedules based on the short-
term results of the noninferiority trial [13]. Type-speciﬁc efﬁcacy
and cross-protection were assumed to be equal for cervical and
non-cervical sites. The duration of vaccine-type efﬁcacy and cross-
protection remains uncertain for two and three doses. Currently,
clinical data show no evidence of waning for three-dose vaccine-
type efﬁcacy after 9.5 years [39] and potential limited duration
of cross-protective efﬁcacy [38]. Given such uncertainty, we var-
ied the average duration of vaccine-type efﬁcacy for three doses
between 20 years and lifelong, and for two doses between 10 years
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nd lifelong. It is important to note that duration of protection is
alculated from the time of the ﬁrst dose. Furthermore, in sce-
arios with limited vaccine duration, each vaccinated individual
s given a speciﬁc duration of protection sampled from a normal
istribution (=varied;  =5 years) [17], as not all individuals will
ose protection at the same time after vaccination. In the base-case
cenarios, cross-protection was assumed to last 10 years. A sce-
ariowas also examinedwhere two-dose schedules do not provide
ross-protection. TheHPV vaccine cost per dose including adminis-
ration was $85. QALY-weights and unit costs were taken from the
iterature [25,26,40–48] (see Supplementary Table 2).
.5. Sensitivity & uncertainty analyses
In univariate sensitivity analysis, vaccine efﬁcacy (for cervical
nd non-cervical sites), duration of protection, percent of anogeni-
al warts due to HPV-6/11, proportion of the male population that
re men-who-have-sex-with-men (MSM), relative risk of disease
n MSM vs. heterosexual men, costs and QALY-weights were varied
etween their minimum and maximum values found in the litera-
ure (Supplementary Tables 1 and 2). Finally, favourable scenarios
or vaccination of boys were examined in multivariate sensitivity
nalysis. Variability of model predictions due to natural history
arameters is presented as the median, and ﬁrst and third quar-
iles of simulation results, referred to as the interquartile ranges
IQR).
. Results
.1. Population-level impact and costs
Table 1 shows the potential population-level effectiveness of
wo-and three-dose schedules assumingdifferentdurationsofpro-
ection (see Supplementary Fig. 2 for post-vaccination dynamics).
nder our base-case (coverage=80%, vaccine-type efﬁcacy=95%)
nd assuming two-dose vaccine duration of protection is 10 years,
wo-dose girls-only vaccination is predicted to prevent a cumulative
3% of HPV-related cancer cases (12% anogenital warts consulta-
ions) over 70 years. Over the same time-horizon, giving a third
ose in a girls-only vaccination programme prevents between 13
nd 15% extra HPV-related cancer cases, if the duration of pro-
ection from three doses is between 25 years and lifelong. The
quivalent expanded reductions in anogenital warts consultations
re between 54 and 60%. Switching to a two-dose girls & boys strat-
gy would prevent an extra 3% HPV-related cancer cases and 9%
nogenital warts consultations compared to a two-dose girls-only
accination policy. However, when assuming the duration of pro-
ection of two doses is 20 or 30 years, the incremental beneﬁts of
iving a third dose to girls-onlyor switching to a two-dose girls&boys
trategy are predicted to be relatively small (e.g., between 2 and 6%
xtra HPV-related cancer cases prevented; Table 1). Of note, the
dditional beneﬁts provided by a third dose to girls-only are mostly
mong females whilst the majority of beneﬁts of switching to a
wo-dose girls & boys strategy are among MSM.
Fig. 1 shows the discounted QALYs-gained and cost offsets for
irls-only and girls & boys vaccination programmes using two- and
hree-dose schedules. The incremental QALYs-saved and cost off-
ets by giving a third dose to girls-only are relatively small when
ssuming that two-dose protection is 20 years or more, but would
ncrease the overall cost of the programme by almost 30%. Unless
wo and three doses provide equal duration of protection, switch-
ng to a two-dose girls & boys vaccination strategy is predicted
o provide similar or lower incremental discounted QALYs-gained
nd cost-offsets than adding a third dose to girls-only. However,
ecause it requires providing twice the additional number of vac-
ine doses, giving two doses to boys would be more than twice the2 (2014) 5845–5853 5847
cost of adding a third dose to girls (incremental cost of a third dose
girls=$109 million vs. two-dose boys=$256 million over 70 years of
vaccination in a population of 10 million, results not shown).
3.2. Cost-effectiveness
Compared to no vaccination, all two- and three-dose girls-only
and girls & boys HPV vaccination strategies investigated produce
cost-effectiveness ratios below the $40,000/QALY-gained cost-
effectiveness threshold (Fig. 2, and see Supplementary Table 3 for
detailed results).
In the base-case, two-dose girls-only vaccination (vs. no
vaccination) consistently produces the lowest incremental cost-
effectiveness ratio with cost/QALY-gained varying between $7900
[IQR: 7000;9700] and $10,400 [IQR: 8800;13,400] (Fig. 2b–f). The
only exception iswhen two-dose duration of protection is assumed
to be 10 years (Fig. 2a). In the sensitivity analysis, two-dose
girls-only vaccination cost-effectiveness ratios remained below
$40,000/QALY-gained (Fig. 3a). The maximum cost per dose for
two-dose girls-only vaccination to remain cost-effective (vs. no vac-
cination) is predicted to be $128, $218 and $252 assuming two-dose
vaccine protection lasts 10, 20 and 30 years, respectively (see Sup-
plementary Fig. 4 and Table 4).
The incremental cost-effectiveness ratio of giving the third dose
of vaccine to girls (i.e., of three-dose girls-only vs. two-dose girls-only)
is estimated to be below $40,000/QALY-gained if: (i) three doses
provide longer protection than two doses (i.e., more than 5 years),
and ii) two-dose protection is less than 30 years (Figs. 2c, d and 3b).
Under most scenarios, two-dose girls & boys vaccination (vs.
two-dose girls-only) provides fewer or similar QALYs-gained and is
more expensive than three-dose girls-only vaccination (i.e., is dom-
inated; Figs. 2a, c–f and 3b). The only exceptions are: (i) if the third
dose provides little or no additional protection to two doses, (ii)
when extreme scenarios for burden of HPV-disease among MSM
are assumed (e.g., 7% males are MSM, the relative risk of disease
among MSM vs. male heterosexuals is 17, and girls-only vaccina-
tion is assumed to have no effect on HPV-related disease incidence
in MSM) or (iii) when vaccine cost for boys is 10–40% of the cost for
girls (Fig. 3b, Supplementary Fig. 3).
Finally, the incremental cost-effectiveness ratio of three-dose
girls & boys vaccination (vs. three-dose girls-only) is greater than
$100,000/QALY-gained under all base-case scenarios andmost sce-
narios investigated in sensitivity analysis (Figs. 2 and 3c). In the
sensitivity analysis, three-dose girls & boys vaccination is estimated
to be less than $40,000/QALY-gained if the cost per dose for girls
and boys is substantially reduced (Supplementary Fig. 4c).
4. Discussion
Our modelling analysis suggests that two-dose girls-only vacci-
nation (compared to no vaccination) is likely to be cost-effective if
vaccine protection is longer than 10 years. Furthermore, two-dose
girls & boys is likely to provide similar or less QALYs-gained and to
be more expensive than three-dose girls-only strategy, unless the
third dose gives no added value or the price for boys is substan-
tially less than the price for girls. Hence, the key question is: how
long does two-dose protection have to be in order for the third
dose to be cost-ineffective among girls? Our results suggest this
threshold duration of protection for two doses is about 30 years.
Hence, if two doses protect for more than 30 years, then the third
dose will have to be priced substantially below $85 to be cost-
effective. Finally, three-dose girls & boys HPV vaccination is unlikely
to be cost-effective compared to three-dose girls-only vaccination,
as shown by most modelling studies, unless the cost of the vaccine
is substantially reduced [49–54].
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Table 1
Health outcomes saved over 70 years after the start of HPV vaccination under base-case assumptionsa (undiscounted; population=10 million).
2-Dose
duration=10 years
2-Dose
duration=20 years
2-Dose
duration=30 years
Cumulative
reduction (%)
Additional cumulative reductionb
(additional % cumulative reduction)c
Cumulative
reduction (%)
Additional cumulative reductionb
(additional % cumulative reduction)c
Cumulative
reduction (%)
Additional cumulative reductionb
(additional % cumulative reduction)c
Strategy 2-dose
Girls only
3-dose
Girls only
3-dose
Girls only
3-dose
Girls only
2-dose
Girls &
boys
2-dose
Girls only
3-dose
Girls only
3-dose
Girls only
3-dose
Girls only
2-dose
Girls &
boys
2-dose
Girls only
3-dose
Girls only
3-dose
Girls only
2-dose
Girls &
boys
Duration
(vaccine types)
10 yearsd 25 yearsd 35 yearsd Lifee 10 yearsd 20 yearsd 25 yearsd 35 yearsd Lifee 20 yearsd 30 yearsd 35 yearsd Lifee 30 yearsd
AGW
consultations
111,066
(11·6)
527,033
(53·9)
568,531
(57·0)
582,422
(60·0)
83,470
(8·6)
550,743
(57·5)
83,710
(8·7)
131,750
(13·7)
133,491
(13·9)
124,531
(13·0)
685,187
(71·4)
1414
(0·1)
776
(0·1)
49,596
(5·1)
Diagnosed
CIN2/3
47,140
(15·4)
89,502
(25·9)
121,485
(32·8)
163,260
(42·0)
13,076
(3·8)
111,443
(32·6)
30,360
(8·2)
52,677
(14·9)
85,107
(23·2)
10,751
(2·8)
144,149
(42·0)
17,704
(5·1)
50,134
(13·3)
12,096
(3·6)
Cancersf
Cervix 4606
(16·4)
4116
(18·2)
4617
(20·1)
5195
(22·5)
832
(2·9)
7266
(29·3)
1155
(4·8)
1696
(6·1)
2251
(8·6)
558
(2·0)
8261
(34·5)
596
(2·2)
1175
(4·5)
421
(1·6)
Anus 448
(10·2)
787
(9·2)
880
(10·3)
919
(10·8)
370
(4·4)
1444
(17·0)
193
(2·3)
281
(3·3)
328
(3·9)
443
(5·2)
1633
(19·3)
87
(1·0)
137
(1·6)
445
(5·2)
Oropharynx 847
(11·2)
1504
(10·3)
1657
(11·3)
1711
(11·7)
577
(3·9)
2736
(18·6)
334
(2·3)
485
(3·3)
541
(3·7)
568
(3·9)
3080
(21·0)
150
(1·0)
209
(1·4)
516
(3·5)
Vulva, vagina
and penile
457
(9·6)
655
(7·1)
684
(7·5)
717
(7·7)
121
(1·4)
1392
(15·0)
162
(1·7)
193
(2·1)
229
(2·5)
106
(1·1)
1528
(16·5)
58
(0·6)
95
(1·4)
92
(1·0)
All cancersg 7961
(13·1)
7191
(12·9)
7890
(14·4)
8576
(15·3)
1954
(3·3)
12,807
(22·3)
1879
(3·2)
2747
(4·3)
3387
(5·6)
1667
(2·8)
14,556
(25·4)
899
(1·5)
1597
(2·7)
1509
(2·6)
AGW: anogenital warts; CIN2/3: cervical intraepithelial neoplasia of grade 2 or 3.
a Base-case: vaccination coverage=80%, vaccine-type efﬁcacy=95%, cross-protective efﬁcacy= see Supplementary Table 1.
b Cumulative reduction: median reduction in the cumulative incidence vs. 2-dose girls-only strategy over 70 years (each parameter set was run 50 times).
c Median of percentage differences compared to 2-dose girls-only. Note: We estimate the median of the differences for each simulation not the difference of medians.
d Duration of cross-protection=10 years.
e Duration of cross-protection= lifelong.
f HPV positive cancers only.
g All cancers: median of totals. Note: We estimate the median of the sums of additional cancer cases prevented for each simulation not the sum of medians.
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Fig. 1. Discounted QALYs-gained and cost offsets over 70 years after the start of HPV vaccination (population=10 million). (a) QALYs-gained and (b) cost offsets for 2-dose
girls-only vaccination protecting for 10 years, 20 years and 30 years; (c) incremental QALYs-gained and (d) cost offsets of giving the 3rd dose or adding 2-dose boys vaccination
to girls programme. Base-case: vaccination coverage=80%, vaccine-type efﬁcacy=95%, cross-protective efﬁcacy= see Supplementary Table 1. Duration of cross-protection is
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lssumed to be lifelong when vaccine-type duration of protection is lifelong, otherw
uality-adjusted life-years.
Our results suggest that a two-dose schedule that provides pro-
ection for more than 30 years would likely prevent the majority
f preventable vaccine-type HPV infections and diseases, which
ntails that the added value of the third dose would be limited.
his is because, at 30 years duration of protection, two-dose vacci-
ation would confer protection during a signiﬁcant proportion of
he peak years of sexual activity and HPV infection (18–35 years).
ur results also indicate that two-dose girls & boys vaccination is
ikely dominated by a three-dose girls-only strategy, because adding
wo doses among boys costs twice as much as adding a third dose
mong girls. However, because these two strategies result in com-
arable QALYs-gained, the price for boys would need to be reduced
y more than half (60%-90% depending on duration of protection,
nd assuming cost for girls ≥$30) to make a two-dose girls & boys
trategy cost-effective vs. three-dose girls-only.
Two key issues must be considered when using these results for
ecision-making. First, the policy decisions regarding alternative
PV vaccine schedules will depend on the evaluation of risks and
ncertainties related to the duration of protection of two and three
oses. Policy-makers could decide that evidence is sufﬁcient for the
mplementation of two-dose girls-only vaccination based on the fol-
owing observations: (i) three doses in young women 16–26 yearsration of cross-protection is assumed to be 10 years. VD: vaccine duration, QALY:
of agehas shown sustained efﬁcacy for almost 10 years [39], (ii) two
doses in girls aged 9–13 years have shown noninferior immuno-
genicity compared to three doses in young women aged 16–26
years [14] and (iii) our results indicate that two-dose girls-only vac-
cination is cost-effective if the vaccine protects for longer than 10
years. On the other hand, the duration of vaccine protection with
two doses remains uncertain. Should this duration be less than 20
years, a third dose extending the duration of protection (≥5 years)
would likely produce substantial additional beneﬁts. Second, for
equity reasons, policy-makers’ or society’swillingness to pay for an
additionalQALY-gainedmaybehigher for two-dose girls&boysvac-
cination than a third dose amonggirls-only. Thepotential additional
beneﬁts of the third dose occur among women and heterosexual
men, who would also beneﬁt from a two-dose girls-only strategy.
However, adding boys to an HPV vaccination programme would
extend beneﬁts to MSM, who do not beneﬁt from the herd effects
of girls-only vaccination [55] and have a disproportionately high
burden of HPV-related disease [56,57]. Hence, policy-makers may
deem a two-dose girls & boys strategy worthwhile even though it is
likely to be less cost-effective than a three-dose girls-only strategy.
Toour knowledge, no studyhas examined the cost-effectiveness
of different HPV vaccination schedules. However, a previous
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Fig. 2. Incremental cost-effectiveness of 2- and 3-dose vaccination strategies. (a) Duration of protection 2 doses =10 years & 3 doses =20 years, (b) duration of protection
2 doses =20 years & 3 doses =20 years, (c) duration of protection 2 doses =20 years & 3 doses =25 years, (d) duration of protection 2 doses =20 years & 3 doses = life (e)
duration of protection 2 doses =30 years & 3 doses =35 years, (f) duration of protection 2 doses =30 years & 3 doses = Life. Base-case: vaccination coverage=80%, vaccine-type
efﬁcacy=95%, cross-protective efﬁcacy= see Supplementary Table 1; duration of cross-protection is assumed to be lifelong when vaccine-type duration of protection is
lifelong, otherwise duration of cross-protection is assumed to be 10 years. QALY: quality-adjusted life-years; population of 170,000 individuals. Each parameter set was run
50 times. Results are themedian and interquartile range (1st and 3rd quartiles ofmodel simulations). The blue line represents the cost-effectiveness threshold ($40,000/QALY-
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ngland [58], examined the potential population-level impact of
wo- and three-dose girls-only HPV vaccination. The conclusions
f both models were similar when examining 40–80% vaccination
overage: the predicted added population-level effectiveness of acost-effectiveness ratios of 2-dose programmes are slightly inﬂuenced by 3-dose
boys vaccination is the most cost-effective strategy between 3-dose girls-only and
third dose at preventing cervical cancer is minimal if the duration
of protection of two doses is at least 20–30 years.
The results from the comparative analysis and the robustness
of our conclusions to vaccine costs/dose and vaccination cover-
age (between 50–80%; see Fig. 3 and Supplementary Table 3),
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Fig. 3. Sensitivity analysis. Cost-effectiveness of (a) 2-dose girls-only vaccination strategy, (b) 3-dose girls-only and 2-dose girls & boys vaccination strategies vs. 2-dose girls-only (only themost cost-effective strategy is shown), and (c)
3-dose girls & boys vaccination strategy vs. the most cost-effective strategy between 3-dose girls-only and 2-dose girls & boys (the comparator for 3-dose girls & boys vaccination is the strategy shown in c). Base-case: coverage=80%,
vaccine-type efﬁcacy=95%, cross-protective efﬁcacy= see Supplementary Table 1. Sensitivity analysis: in the sensitivity analyses, only the parameters indicated in the description were varied, holding other parameter values
at the base-case level. Max (Min) burden of disease: all costs and QALYs-lost parameters, and % HPV-6/11 in AGW are given their maximum (minimum) values from the literature (Supplementary Table 2). Deﬁnitions. QALY:
quality-adjusted life-years; coverage: vaccination coverage; AGW: anogenital warts; MSM: men-who-have-sex-with-men; RR: relative risk of disease in MSM vs. heterosexual males; ICER: incremental cost-effectiveness ratio.
Each parameter set was run 50 times. Solid dots represent the median, boxes the 1st and 3rd quartiles of model simulations, and the “error-bars” the 10th and 90th percentiles of model simulations.
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uggests that the main cost-effectiveness conclusions of this paper
re likely to be generalisable to other high income countries with
PV epidemiology, health care costs and cervical screening sim-
lar to England and Canada. However, our results should not be
xtrapolated to resource-poor settings due to differences in sexual
ehaviour and HPV epidemiology.
A limitation of our analysis is the validity of data on the pro-
ortion of MSM in the population and the burden of disease within
his population. However, even when the proportion of MSM was
ssumed to be high (7% vs. 3% in the base-case), vaccinating boys
ith two doses remained dominated by three-dose girls-only vac-
ination. A second limitation of the analysis is that our model
ssumes no herd-protection from girls-only vaccination to MSM.
erd-protection to MSM is only included in scenarios with male
accination, potentially overestimating the impact of including
oys in vaccination programmes. However, no herd-immunity has
een observed inMSM following the introduction of girls-only HPV
accination [59].
As recommended by good modelling practice, we conducted
nternal, between-model and external/predictive validation [60].
irst, HPV-ADVISEwas calibrated tohighly-stratiﬁedCanadiandata
n sexual behaviour, natural history and cervical cancer screening
internal validation), and model predictions were performed using
ultiple good ﬁtting parameter sets. Secondly, as discussed above,
ur two-dose effectiveness predictions are consistent with those
rom a model used to inform HPV immunisation decisions in
ngland (between-model validation) [58]. Finally, our model qual-
tatively reproduces short-term post-vaccination data showing
mportant and rapid declines in anogenital warts and herd effects
n young heterosexual men from vaccinating girls-only with high
overage, such as those reported for Australia (external/predictive
alidation) [55,59,61] (see Supplementary Fig. 4).
Our cost-effectiveness analysis provides new evidence to help
ecision-makers weigh the potential risks and beneﬁts of reducing
PV vaccination schedules from three to two doses for different
ssumptions about duration of protection. Independently of the
chedule implemented, careful long-term surveillance is essential
s duration of protection remains the key uncertainty in the effec-
iveness of HPV vaccination programmes.
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